Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you, despite some gloomy rain clouds descending upon the Pharmalot campus. After all, there is no reason not to maintain sunny spirits. As the Morning Mayor used to say: Every new day should be unwrapped like a precious gift. This might resonate more deeply these days, yes? Well, while you brush up on philosophical slogans, here are a few items of interest to mull over. Hope your day goes well, and please do keep in touch. We enjoy people who wear masks and provide saucy tips. …

As the U.S. accelerates the hunt for a Covid-19 vaccine, tensions have erupted between government scientists and Moderna (MRNA), one of the leading developers, Reuters reports. The federal government is supporting Moderna’s vaccine project with nearly half a billion dollars and chose it as one of the first to enter large-scale human trials. But the company, which has never produced an approved vaccine or run a large trial, has squabbled with government scientists over the process, delayed delivering trial protocols, and resisted expert advice on how to run the study.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.